Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or...
Chronic Myeloproliferative DisordersKidney Cancer10 moreRATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth. PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who are receiving chemotherapy with or without radiation therapy before donor bone marrow transplantation.
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer...
AnemiaLeukemia4 moreRATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether epoetin alfa or epoetin beta are more effective when given with or without iron infusion in treating anemia in patients with cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa or epoetin beta to compare how well they work with or without iron infusion in treating anemia in patients with cancer.
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
Chronic Myeloproliferative DisordersDrug/Agent Toxicity by Tissue/Organ7 moreRATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of amifostine plus combination chemotherapy in treating patients with advanced cancer.
Observational Study of Home Administration of Carfilzomib
Multiple MyelomaHematologic DiseasesThe purpose of this study is to evaluate the feasibility of an at home administration program for carfilzomib patients.
Prevalence of Asymptomatic Thrombosis in Multiple Myeloma
ThrombosisMultiple MyelomaMalignant hemopathies, such as solid cancers, increase the risk of venous and arterial thromboembolic events. The incidence of symptomatic venous thromboembolic events is particularly high in myeloma, linked to the usual risk factors for venous thromboembolic disease, biological risk factors specific to myeloma, and especially to its treatments. The prevalence of asymptomatic venous thromboembolic events and arterial events are not known to date and remain important data for planning a possible randomized study to determine the most suitable thromboprophylaxis in these patients.
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
Brain and Central Nervous System TumorsChronic Myeloproliferative Disorders9 moreRATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage cancer. PURPOSE: This clinical trial is studying perceptions of burden in patients with late-stage cancer and their caregivers.
Collecting and Storing Blood Samples From Patients With Cancer
Brain and Central Nervous System TumorsChronic Myeloproliferative Disorders11 moreRATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood samples from patients with cancer.
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed...
Multiple MyelomaThis study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, the investigators will use data from the phase 2 clinical trial (MagnetisMM-3). The investigators will also use data from multiple real-world sources, representing the SOC in clinical practice. This study does not seek any participants for enrollment. The investigators will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help the investigators to know how well elranatamab can be used for RRMM treatment.
Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic...
Multiple MyelomaThe purpose of this study is to characterize the multiple myeloma (MM) participants with symptomatic relapse and/or refractory disease in Spain.
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
Acute Myelogenous LeukemiaMultiple Myeloma5 moreThis is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.